Caseware UK (AP4) 2024.0.164 2024.0.164 2024-12-31 2024-12-31 2024-01-01 false No description of principal activity 1 1 true true false 13866837 2024-01-01 2024-12-31 13866837 2023-01-01 2023-12-31 13866837 2024-12-31 13866837 2023-12-31 13866837 2023-01-01 13866837 2 2024-01-01 2024-12-31 13866837 d:Director1 2024-01-01 2024-12-31 13866837 e:CurrentFinancialInstruments 2024-12-31 13866837 e:CurrentFinancialInstruments 2023-12-31 13866837 e:CurrentFinancialInstruments e:WithinOneYear 2024-12-31 13866837 e:CurrentFinancialInstruments e:WithinOneYear 2023-12-31 13866837 e:ShareCapital 2024-01-01 2024-12-31 13866837 e:ShareCapital 2024-12-31 13866837 e:ShareCapital 2023-01-01 2023-12-31 13866837 e:ShareCapital 2023-12-31 13866837 e:ShareCapital 2023-01-01 13866837 e:OtherMiscellaneousReserve 2024-01-01 2024-12-31 13866837 e:OtherMiscellaneousReserve 2024-12-31 13866837 e:OtherMiscellaneousReserve 2 2024-01-01 2024-12-31 13866837 e:OtherMiscellaneousReserve 2023-01-01 2023-12-31 13866837 e:OtherMiscellaneousReserve 2023-12-31 13866837 e:OtherMiscellaneousReserve 2023-01-01 13866837 e:RetainedEarningsAccumulatedLosses 2024-01-01 2024-12-31 13866837 e:RetainedEarningsAccumulatedLosses 2024-12-31 13866837 e:RetainedEarningsAccumulatedLosses 2 2024-01-01 2024-12-31 13866837 e:RetainedEarningsAccumulatedLosses 2023-01-01 2023-12-31 13866837 e:RetainedEarningsAccumulatedLosses 2023-12-31 13866837 e:RetainedEarningsAccumulatedLosses 2023-01-01 13866837 d:OrdinaryShareClass1 2024-01-01 2024-12-31 13866837 d:OrdinaryShareClass1 2024-12-31 13866837 d:OrdinaryShareClass1 2023-12-31 13866837 d:FRS102 2024-01-01 2024-12-31 13866837 d:Audited 2024-01-01 2024-12-31 13866837 d:FullAccounts 2024-01-01 2024-12-31 13866837 d:PrivateLimitedCompanyLtd 2024-01-01 2024-12-31 13866837 d:SmallCompaniesRegimeForAccounts 2024-01-01 2024-12-31 13866837 e:ShareCapital 2 2024-01-01 2024-12-31 13866837 f:PoundSterling 2024-01-01 2024-12-31 xbrli:shares iso4217:GBP xbrli:pure

Registered number: 13866837 TIGERMED UK LTD FINANCIAL STATEMENTS INFORMATION FOR FILING WITH THE REGISTRAR FOR THE YEAR ENDED 31 DECEMBER 2024
TIGERMED UK LTD REGISTERED NUMBER: 13866837 BALANCE SHEET AS AT 31 DECEMBER 2024
|  | 2024 |  | 2023
Note |  | £ |  | £
Current assets |  |  |  |  |
Debtors: amounts falling due within one year | 4 | 21,442 |  | 20,199 |
Cash at bank and in hand | 5 | 387,722 |  | 238,987 |
|  | 409,164 |  | 259,186 |
Creditors: amounts falling due within one year | 6 | (13,189) |  | (51,752) |
Net current assets |  |  | 395,975 |  | 207,434
Total assets less current liabilities |  |  | 395,975 |  | 207,434
Net assets |  |  | 395,975 |  | 207,434
Capital and reserves |  |  |  |  |
Called up share capital | 7 |  | 1,000 |  | 1,000
Other reserves | 8 |  | 641,062 |  | 329,960
Profit and loss account | 8 |  | (246,087) |  | (123,526)
|  |  | 395,975 |  | 207,434
The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities. The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime. The Company has opted not to file the statement of income and retained earnings in accordance with provisions applicable to companies subject to the small companies' regime. The financial statements were approved and authorised for issue by the board and were signed on its behalf on 2 September 2025.
X Shi
Director
The notes on pages 3 to 8 form part of these financial statements. Page 1
TIGERMED UK LTD STATEMENT OF CHANGES IN EQUITY FOR THE YEAR ENDED 31 DECEMBER 2024
| Called up share capital | Other reserves | Profit and loss account | Total equity
| £ | £ | £ | £
At 1 January 2023 | 1,000 | 329,960 | (6,229) | 324,731
Comprehensive income for the year |  |  |  |
Loss for the year | - | - | (117,297) | (117,297)
Total comprehensive income for the year | - | - | (117,297) | (117,297)
At 1 January 2024 | 1,000 | 329,960 | (123,526) | 207,434
Comprehensive income for the year |  |  |  |
Loss for the year | - | - | (122,561) | (122,561)
Total comprehensive income for the year | - | - | (122,561) | (122,561)
Contributions by and distributions to owners |  |  |  |
Capital contibutions | - | 311,102 | - | 311,102
At 31 December 2024 | 1,000 | 641,062 | (246,087) | 395,975
| The notes on pages 3 to 8 form part of these financial statements.
Page 2
TIGERMED UK LTD NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024
1. | General information
Tigermed UK Ltd is a private company limited by shares. The company was incorporated in the United Kingdom and is registered in England and Wales. The registered office is Dept 849a, 196 High Road, Wood Green, London, United Kingdom, N22 8HH. The registered number is 13866837. 2.Accounting policies
| 2.1 | Basis of preparation of financial statements
The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view. The following principal accounting policies have been applied:
| 2.2 | Going concern
The directors are satisfied that the going concern assessment is passed as a result of its strong financial and cash position. The company is also appropriately supported by its parent company within the group. Thus the company remains in a strong position for the future.
| 2.3 | Foreign currency translation
Functional and presentation currency The Company's functional and presentational currency is GBP. Transactions and balances Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions. At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined. Foreign exchange gains and losses resulting from the settlement of transactions and from the translation at period-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in profit or loss except when deferred in other comprehensive income as qualifying cash flow hedges. Foreign exchange gains and losses that relate to borrowings and cash and cash equivalents are presented in the Statement of income and retained earnings within 'finance income or costs'. All other foreign exchange gains and losses are presented in profit or loss within 'other operating income'. Page 3
TIGERMED UK LTD NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024 2.Accounting policies (continued)
| 2.4 | Revenue
Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised: Rendering of services Revenue from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied: ∙the amount of revenue can be measured reliably; ∙it is probable that the Company will receive the consideration due under the contract; ∙the stage of completion of the contract at the end of the reporting period can be measured reliably; and ∙the costs incurred and the costs to complete the contract can be measured reliably.
| 2.5 | Pensions
Defined contribution pension plan The Company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the Company pays fixed contributions into a separate entity. Once the contributions have been paid the Company has no further payment obligations. The contributions are recognised as an expense in profit or loss when they fall due. Amounts not paid are shown in other creditors as a liability in the Balance sheet. The assets of the plan are held separately from the Company in independently administered funds.
| 2.6 | Debtors
Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.
| 2.7 | Cash and cash equivalents
Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.
| 2.8 | Creditors
Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method. Page 4
TIGERMED UK LTD NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024 2.Accounting policies (continued)
| 2.9 | Financial instruments
The Company has elected to apply the provisions of Section 11 “Basic Financial Instruments” of FRS 102 to all of its financial instruments. Financial instruments are recognised in the Company's Balance sheet when the Company becomes party to the contractual provisions of the instrument. Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously. Basic financial assets Basic financial assets, which include trade and other debtors, cash and bank balances, are initially measured at their transaction price (adjusted for transaction costs except in the initial measurement of financial assets that are subsequently measured at fair value through profit and loss) and are subsequently carried at their amortised cost using the effective interest method, less any provision for impairment, unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Discounting is omitted where the effect of discounting is immaterial. The Company's cash and cash equivalents, trade and most other debtors due with the operating cycle fall into this category of financial instruments. Other financial assets Other financial assets, which includes investments in equity instruments which are not classified as subsidiaries, associates or joint ventures, are initially measured at fair value, which is normally the recognised transaction price. Such assets are subsequently measured at fair value with the changes in fair value being recognised in the profit or loss. Where other financial assets are not publicly traded, hence their fair value cannot be measured reliably, they are measured at cost less impairment. Impairment of financial assets At the end of each reporting period financial assets measured at amortised cost are assessed for objective evidence of impairment. If an asset is impaired the impairment loss is the difference between the carrying amount and the present value of the estimated cash flows discounted at the asset’s original effective interest rate. The impairment loss is recognised in profit or loss. If there is a favourable change in relation to the events surrounding the impairment loss then the impairment can be reviewed for possible reversal. The reversal will not cause the current carrying amount to exceed the original carrying amount had the impairment not been recognised. The impairment reversal is recognised in the profit or loss. Basic financial liabilities Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the Company after the deduction of all its liabilities. Page 5
TIGERMED UK LTD NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024 2.Accounting policies (continued)
| 2.9 | Financial instruments (continued)
Basic financial liabilities, which include trade and other creditors, bank loans and other loans are initially measured at their transaction price (adjusting for transaction costs except in the initial measurement of financial liabilities that are subsequently measured at fair value through profit and loss). When this constitutes a financing transaction, whereby the debt instrument is measured at the present value of the future payments discounted at a market rate of interest, discounting is omitted where the effect of discounting is immaterial. Debt instruments are subsequently carried at their amortised cost using the effective interest rate method. Trade creditors are obligations to pay for goods and services that have been acquired in the ordinary course of business from suppliers. Trade creditors are classified as current liabilities if the payment is due within one year. If not, they represent non-current liabilities. Trade creditors are initially recognised at their transaction price and subsequently are measured at amortised cost using the effective interest method. Discounting is omitted where the effect of discounting is immaterial. Other financial instruments Derivatives, including forward exchange contracts, futures contracts and interest rate swaps, are not classified as basic financial instruments. These are initially recognised at fair value on the date the derivative contract is entered into, with costs being charged to the profit or loss. They are subsequently measured at fair value with changes in the profit or loss. Debt instruments that do not meet the conditions as set out in FRS 102 paragraph 11.9 are subsequently measured at fair value through the profit or loss. This recognition and measurement would also apply to financial instruments where the performance is evaluated on a fair value basis as with a documented risk management or investment strategy. Derecognition of financial instruments Derecognition of financial assets Financial assets are derecognised when their contractual right to future cash flow expire, or are settled, or when the Company transfers the asset and substantially all the risks and rewards of ownership to another party. If significant risks and rewards of ownership are retained after the transfer to another party, then the Company will continue to recognise the value of the portion of the risks and rewards retained. Derecognition of financial liabilities Financial liabilities are derecognised when the Company's contractual obligations expire or are discharged or cancelled. Page 6
TIGERMED UK LTD NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024
3. | Employees
| The average monthly number of employees, including directors, during the year was 1 (2023 - 1).
4. | Debtors
|  |  |  |  | 2024 | 2023
|  |  |  |  | £ | £
| Amounts owed by group undertakings | 20,944 | 1,000
| Other debtors | - | 18,668
| Prepayments and accrued income | 498 | 531
|  | 21,442 | 20,199
5. | Cash and cash equivalents
|  |  |  |  | 2024 | 2023
|  |  |  |  | £ | £
| Cash at bank and in hand | 387,722 | 238,987
|  | 387,722 | 238,987
6. | Creditors: Amounts falling due within one year
|  |  |  |  | 2024 | 2023
|  |  |  |  | £ | £
| Trade creditors | 410 | -
| Other taxation and social security | 856 | 9,878
| Other creditors | 2,528 | 3,790
| Accruals and deferred income | 9,395 | 38,084
|  | 13,189 | 51,752
7. | Share capital
|  |  |  |  | 2024 | 2023
|  |  |  |  | £ | £
|  | Allotted, called up and fully paid |  |
|  | 1,000 (2023 - 1,000) Ordinary shares of £1.00 each | 1,000 | 1,000
Page 7
TIGERMED UK LTD NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024
8. | Reserves
Other reserves The other reserves figure of £641,062 relates to a capital contribution. Profit and loss account Includes all current and prior period retained earnings.
9. | Pension commitments
The Company operates a defined contributions pension plan. The assets of the plan are held separately from those of the Company in an independently administered fund. The pension cost charge represents contributions payable by the Company to the fund and amounted to £9,137 (2023 - £1,906). Contributions totalling £174 (2023 - £3,790) were payable to the fund at the balance sheet date and are included in other creditors.
10. | Related party transactions
| The Company has taken advantage of the exemption allowed by FRS 102 not to disclose transactions with other wholly owned members of the group.
11. | Controlling party
The immediate parent company is Hong Kong Tigermed Healthcare Technology Co Ltd which is incorporated and registered in Hong Kong, China. The ultimate controlling parent is Hangzhou Tigermed Consulting Co. Ltd which is incorporated and registered in Hangzhou, China. The Company is included in the consolidated accounts of the ultimate controlling parent company, Hangzhou Tigermed Consulting Co. Ltd, whose registered address is Room 2001-2010, Fl.20, Building 8, No.19 Jugong Road, Xixing Street, Binjiang District, Hangzhou, China, 310053. This is the smallest group to which the Company belongs and for which group financial statements are prepared.
12. | Auditors' information
The auditors' report on the financial statements for the year ended 31 December 2024 was unqualified. The audit report was signed on 2 September 2025 by Daniel Reid FCA (Senior statutory auditor) on behalf of FLB Audit LLP.
Page 8